Inmagene Bio charts backdoor to U.S. listing with offshore acquisition
The biotech company’s merger with Ikena Oncology will bring in $175 million in fresh funds, including $75 million from an oversubscribed private placement Key Takeaways: Inmagene Bio plans to merge…
Recent Articles
RELATED ARTICLES
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK -
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US
-
Seyond may get stuck in slow-moving SPAC lane to Hong Kong listing
7855.HK
-
Synagistics holds potential to enliven moribund Hong Kong SPAC market
2562.HK
- The dilemma of the China-shedding strategy
- Stealthy eLong Power sneaks closer to U.S. listing
- CHINA BULLETIN: Manufacturing Déjà Vu
